Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
26 hedge funds and large institutions have $26.5M invested in Bellerophon Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 3 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
1.32% less ownership
Funds ownership: 54.67% → 53.36% (-1.3%)
9% less capital invested
Capital invested by funds: $29.1M → $26.5M (-$2.66M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$189K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$101K |
| 3 |
Renaissance Technologies
New York
|
+$74.7K |
| 4 |
LPL Financial
San Diego,
California
|
+$15.1K |
| 5 |
Goldman Sachs
New York
|
+$8.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$631K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$202K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$103K |
| 4 |
BlackRock
New York
|
-$28.1K |
| 5 |
AC
Armistice Capital
New York
|
-$25.6K |
BLPH Hedge Fund Activity: Q2 2019 in Review
26 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2019, worth a combined $26.5M — down 9.1% from $29.1M a quarter earlier.
Fund positioning in BLPH was balanced in Q2 2019: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 6 trimmed.
The largest buyer was Telemetry Investments, adding an estimated $189K. The largest seller was Arch Venture Management, exiting entirely with an estimated $631K sold.
- 26 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $26.5M of Bellerophon Therapeutics, Inc. stock for Q2 2019, down 9.1% quarter-over-quarter.
- 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2019 and 3 closed out, a net change of 0 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q2 2019 was Telemetry Investments, an estimated $189K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q2 2019 was Arch Venture Management, an estimated $631K sold.
Based on aggregated 13F filings for Q2 2019.